These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. Vaglini M; Belli F; Santinami M; Arienti F; Parmiani G; Persiani L; Santoro N; Grazia Inglese M; D'Elia F; Cascinelli N Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457 [TBL] [Abstract][Full Text] [Related]
5. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646 [TBL] [Abstract][Full Text] [Related]
6. Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Olofsson R; Lindberg E; Karlsson-Parra A; Lindnér P; Mattsson J; Andersson B Int J Hyperthermia; 2013 May; 29(3):234-8. PubMed ID: 23590363 [TBL] [Abstract][Full Text] [Related]
7. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175 [TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492 [TBL] [Abstract][Full Text] [Related]
9. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Ridolfi L; Ridolfi R Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445 [TBL] [Abstract][Full Text] [Related]
10. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study. Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381 [TBL] [Abstract][Full Text] [Related]
11. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma]. Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328 [TBL] [Abstract][Full Text] [Related]
12. [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates]. Assmann K; Nashan D; Grabbe S; Luger TA; Metze D Hautarzt; 2002 Aug; 53(8):554-7. PubMed ID: 12221472 [TBL] [Abstract][Full Text] [Related]
13. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917 [TBL] [Abstract][Full Text] [Related]
14. Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Kaplan B; Moy RL Dermatol Surg; 2000 Nov; 26(11):1037-40. PubMed ID: 11096390 [TBL] [Abstract][Full Text] [Related]
15. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759 [TBL] [Abstract][Full Text] [Related]
17. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Kirchner HH; Atzpodien J; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119 [TBL] [Abstract][Full Text] [Related]
18. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362 [TBL] [Abstract][Full Text] [Related]
19. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626 [TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]